WO2010029458A2 - A process for preparing quetiapine fumarate - Google Patents
A process for preparing quetiapine fumarate Download PDFInfo
- Publication number
- WO2010029458A2 WO2010029458A2 PCT/IB2009/053760 IB2009053760W WO2010029458A2 WO 2010029458 A2 WO2010029458 A2 WO 2010029458A2 IB 2009053760 W IB2009053760 W IB 2009053760W WO 2010029458 A2 WO2010029458 A2 WO 2010029458A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- quetiapine
- sodium
- quetiapine fumarate
- thiazepine
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- URKOMYMAXPYINW-UHFFFAOYSA-N OCCOCCN(CC1)CCN1C1=Nc2ccccc2Sc2c1cccc2 Chemical compound OCCOCCN(CC1)CCN1C1=Nc2ccccc2Sc2c1cccc2 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
Definitions
- the present invention relates to an improved process for preparing Quetiapine fumarate of formula (I).
- Quetiapine is used as Antipsychotic. It is antipsychotic, psycholeptics and antidepressant class drug. It is dopamine antagonist and 5HT antagonist. It is used in the treatment of schizophrenia, bipolar diseases and psychosis. It is also used in the treatment of anxiety and depression.
- Another object of the present invention is to provide a process which gives Quetiapine fumarate with high purity.
- present invention provides a process for preparation of Quetiapine fumarate (I)
- present invention provides a process for preparation of Quetiapine fumarate (I)
- the present invention provides a process for purification of Quetiapine fumarate (I) comprising steps of
- 11-chlorodibenzo [b,f][l,4]thiazepine (III) is heated with l-(2-hydroxyethoxy)ethylpiperazine dihy- drochloride (IV) in the presence of base in sulfolane at about 95 0 C to about 100 0 C for about 4 hours.
- Other solvent in combination with sulfolane can also be used.
- a combination of toluene and sulfolane is used as solvent in this reaction step.
- the base used is selected from potassium carbonate, sodium carbonate, lithium carbonate, sodium acetate, potassium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, potassium tert-butoxide, l,8-diazobicyclo[5,4,0]undecene, N- benzyltrimethylammonium hydroxide, triethyl amine, tributyl amine, N,N-diisopropyl ethylamine, N,N-dimethylaniline, N,N-diethylaniline, pyridine, picolines, N,N-dimethylaminopyridine, N-methylmorpholine and the like or mixtures thereof.
- An aqueous solution of the base can also be used. After completion of the reaction, the reaction mixture is quenched with water. The reaction mixture is extracted with ethyl acetate. The organic layer is separated and evaporated to dryness to give Quetiapine (V) as viscous oil. A pre -heated solution at about 7O 0 C to about 75 0 C of fumaric acid in methanol is added to a solution of Quetiapine (V) in methanol at about 7O 0 C to about 75 0 C and further heated for 30min at the same temperature. The reaction mixture is cooled to about 5 0 C to about 15 0 C. The separated solid is filtered, washed with chilled methanol and suck dried. The wet cake is used for purification.
- the present invention provides a process for purification of Quetiapine fumarate (I) comprising steps of
- Impure Quetiapine fumarate means Quetiapine fumarate having HPLC purity less than 99.8%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
The present invention relates to a process for preparing Quetiapine fumarate of formula (I)
Description
Description
Title of Invention: A PROCESS FOR PREPARING QUETIAPINE
FUMARATE
[i]
Field of the invention
[2]
[3] The present invention relates to an improved process for preparing Quetiapine fumarate of formula (I).
[5]
Background of the invention
[6]
[7] The chemical name of Quetiapine is 2-[2-(4-Dibenzo[b,/][l,4] thiazepin-1
1-yl-l-piperazinyl) ethoxy]ethanol and formula is C2IH25N3O2S and molecular weight is 383.51. The drug is used in its fumarate salt. The current pharmaceutical product containing this drug is being sold by Astrazeneca using the tradename Seroquel and Seroquel XR, in the form of oral tablets.
[8]
[9] Quetiapine is used as Antipsychotic. It is antipsychotic, psycholeptics and antidepressant class drug. It is dopamine antagonist and 5HT antagonist. It is used in the treatment of schizophrenia, bipolar diseases and psychosis. It is also used in the treatment of anxiety and depression.
[10]
[11] US patent 4,879,288 describes a process for the preparation of Quetiapine fumarate which is shown in the scheme-I.
Quetiapme fumarate (I)
[13] Scheme-I [14] [15] The process involves reacting dibenzo[b,f][l,4] thiazepine-l l(10-H)-one (II) with phosphorous oxychloride in the presence of N,N-dimethylaniline to give imino chloride (III); which is further reacted with l-(2-hydroxyethoxy) ethylpiperazine (IV) in xylene to give Quetiapine (V). Quetiapine is purified by flash chromatography and then converted into its fumarate salt by reacting it with fumaric acid in ethanol to give Quetaipine fumarate (I). The yield and purity obtained by this process is low. Further, this process requires chromatographic purification of Quetiapine before converting it to its fumarate salt. No purification process of Quetiapine fumarate is disclosed in this patent to enhance the purity of Quetiapine fumarate.
[16] [17] It is therefore, a need to develop an easy to operate, industrially feasible process which also provides good yield and high purity of Quetiapine fumarate . The present invention addresses these needs.
[18] [19] Present inventors have directed their research work towards developing a process for the preparation of Quetiapine fumarate which provides good yield and purity. The present inventors observed that using sulfolane as solvent in condensation step of imino chloride (III) with l-(2-hydroxyethoxy)ethylpiperazine (IV) instead of xylene increases yield and purity of quetiapine and which need not require to purify Quetiapine by chromatography before converting it to its fumarate salt.
[20]
Summary of the invention
[22] Accordingly, it is an object of the present invention to provide a process for the preparation of Quetiapine fumarate.
[23] [24] Another object of the present invention is to provide a process which gives Quetiapine fumarate with high purity.
[25] [26] Another object of the present invention is to provide a process for the preparation of Quetiapine fumarate which is operationally simple and cost effective.
[27] [28] Accordingly, present invention provides a process for preparation of Quetiapine fumarate (I)
[30] [31] comprising a step of reacting 11-chlorodibenzo [b,f][l,4]thiazepine (III)
[33] [34] with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV) [35]
HN OH
2HCI
IV
[39] [40] Accordingly, present invention provides a process for preparation of Quetiapine fumarate (I)
[42] [43] comprising steps of: [44] (i) dibenzo[b,f][l,4]thiazepine-l l(10-H)-one (II)
[46] [47] with phosphorous oxychloride in the presence of N,N-dimethylaniline in toluene to give 11-chlorodibenzo [b,f][l,4]thiazepine (III);
[49]
[50] (ii) reacting 11-chlorodibenzo [b,f][l,4]thiazepine (III) with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV)
HN N ^"-"^ ^^ OH
\ / .2HCI
IV
[52] [53] in the presence of a base and sulfolane to give Quetiapine (V);
[55] [56] (iii) converting Quetiapine (V) to Quetiapine fumarate (I) by reacting it with fumaric acid in methanol.
[57] [58] The present invention provides a process for purification of Quetiapine fumarate (I) comprising steps of
[59] (a) heating impure Quetiapine fumarate (I) with methanol [60] (b) adding water dropwise till clear solution obtained [61] (c) cooling the reaction mixture to obtain pure Quetiapine fumarate (I). [62]
Detailed description of the invention
[63] [64] The present invention provides an improved process for preparation of Quetiapine fumarate (I)
[70] with phosphorous oxychloride in the presence of N,N-dimethylaniline in toluene to give 11-chlorodibenzo [b,f][l,4] thiazepine (III);
[72] [73] (ii) reacting 11-chlorodibenzo [b,f][l,4] thiazepine (III) with l-(2-hydroxyethoxy) ethylpiperazine dihydrochloride (IV)
[74]
HN OH
2HCI
IV
[75] [76] in the presence of a base and sulfolane to give Quetiapine (V);
[78] [79] (iii) converting Quetiapine (V) to Quetiapine fumarate (I) by reacting it with fumaric acid in methanol.
Quetiapine fumarate (I)
[83] Scheme-II [84] [85] In the process of present invention, dibenzo[b,f][l,4]thiazepine-l l(10-H)-one (II) is heated with Phosphorous oxychloride in the presence of N,N-Dimethyl aniline in toluene at about 11O0C to about 1150C for 5 to 6 hours. After completion of reaction, organic layer is washed with water. The solvent from organic layer is distilled out under reduced pressure at about 450C to about 5O0C to give 11-chlorodibenzo [b,f][l,4]thiazepine (III) which is used as such for next step. 11-chlorodibenzo [b,f][l,4]thiazepine (III) is heated with l-(2-hydroxyethoxy)ethylpiperazine dihy- drochloride (IV) in the presence of base in sulfolane at about 950C to about 1000C for about 4 hours. Other solvent in combination with sulfolane can also be used. For example a combination of toluene and sulfolane is used as solvent in this reaction step. The base used is selected from potassium carbonate, sodium carbonate, lithium carbonate, sodium acetate, potassium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, potassium tert-butoxide, l,8-diazobicyclo[5,4,0]undecene, N- benzyltrimethylammonium hydroxide, triethyl amine, tributyl amine, N,N-diisopropyl ethylamine, N,N-dimethylaniline, N,N-diethylaniline, pyridine, picolines, N,N-dimethylaminopyridine, N-methylmorpholine and the like or mixtures thereof. An aqueous solution of the base can also be used. After completion of the reaction, the reaction mixture is quenched with water. The reaction mixture is extracted with ethyl acetate. The organic layer is separated and evaporated to dryness to give Quetiapine (V) as viscous oil. A pre -heated solution at about 7O0C to about 750C of fumaric acid in methanol is added to a solution of Quetiapine (V) in methanol at about 7O0C to
about 750C and further heated for 30min at the same temperature. The reaction mixture is cooled to about 50C to about 150C. The separated solid is filtered, washed with chilled methanol and suck dried. The wet cake is used for purification.
[86]
[87] The present invention provides a process for purification of Quetiapine fumarate (I) comprising steps of
[88] (a) heating impure Quetiapine fumarate (I) with methanol
[89] (b) adding water dropwise till clear solution obtained
[90] (c) cooling the reaction mixture to obtain pure Quetiapine fumarate (I).
[91]
[92] Impure Quetiapine fumarate' means Quetiapine fumarate having HPLC purity less than 99.8%.
[93] In the purification of Quetiapine fumarate, methanol is added to the wet cake of impure Quetiapine fumarate obtained in above process and heated at about 650C to about 7O0C. D. M. Water is added drop wise at the same temperature till clear solution is obtained. The reaction mixture is stirred for 30 min at the same temperature and then cooled to about 50C to about 15 0C. The separated solid is filtered, washed with chilled methanol and suck dried. The solid is dried under vacuum at about 550C to about 6O0C to give pure Quetiapine fumarate (I)
[94] The following examples illustrate the invention further. It should be understood, however, that the invention is not confined to the specific limitations set forth in the individual examples but rather to the scope of the appended claims.
[95]
[96] Example-1
[97]
[98] Preparation of 11-chlorodibenzo [b,f][l,4]thiazepine (III)
[99] dibenzo[b,f][l,4]thiazepine-l l(10-H)-one (II) (100 g) was heated with phosphorous oxychloride (67.46 g) in the presence of N,N-Dimethyl aniline (106.63 g) in toluene (500 ml) at 11O0C to 1150C for 5 to 6 hours. After completion of the reaction, organic layer was washed twice with water (2x 200 ml). The solvent from organic layer was distilled out under reduced pressure at 450C to 5O0C to give residue 11-chlorodibenzo [b,f][l,4]thiazepine (III) which was used as such for next step.
[100]
[101] Example-2
[102]
[103] Preparation of Quetiapine Base (V)
[104] Residue 11-chlorodibenzo [b,f][l,4]thiazepine (III) obtained from Example-1 was heated with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV) (119.65 g) in the
presence of potassium carbonate (213.12 g) in sulfolane (400 ml) at 950C to 1000C for about 4 hours. After completion of reaction, the reaction mixture was quenched with D. M. Water (1000 ml). The reaction mixture is extracted with ethyl acetate (2x300 ml). Organic layer is separated evaporated to dryness under vacuum to give Quetiapine (V) as viscous oil which was used as such for the next step.
[105]
[106] Example-3
[107]
[108] Preparation of Quetiapine Fumarate (I)
[109] A pre-heated solution at 7O0C to 750C of Fumaric acid (26.55 g) in methanol (300 ml) was added to the solution of Quetiapine [obtained in Example-2] in methanol(300 ml) at 7O0C to 750C. The reaction mixture was stirred for 30 min at 7O0C to 750C. The reaction mixture was cooled to 150C. The separated solid was filtered, washed with chilled methanol (100 ml) and suck dried. The wet cake of Quetiapine fumarate was used as such for the next step.
[HO]
[111] Example-4
[112]
[113] Purification of Quetiapine Fumarate (I)
[114] Quetiapine fumarate wet cake obtained from Example-4 was heated in methanol
(1200 ml) at 650C to 7O0C. D. M. Water (approximately 50 ml) was added drop wise at the same temperature till clear solution was obtained. The reaction mixture was stirred for 30 min at 65-7O0C. The reaction mixture was cooled to 150C. The separated solid was filtered, washed with chilled methanol (100 ml) and dried under vacuum at 550C to 6O0C to give pure Quetiapine fumarate (122.0 g)
[115] Overall yield: 55.56%
[116] Purity (by HPLC): 99.84%
[117]
Claims
[Claim 1] 1. A process for preparation of Quetiapine fumarate (I)
with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV)
HN OH
2HCI
IV in the presence of a base and sulfolane to give Quetiapine (V);
[Claim 2] 2. A process for preparation of Quetiapine fumarate (I)
(i) dibenzo[b,f][l,4]thiazepine-l l(10-H)-one (II)
with phosphorous oxychloride in the presence of N,N-dimethylaniline in toluene to give 11-chlorodibenzo [b,f][l,4]thiazepine (III);
(ii) reacting 11-chlorodibenzo [b,f][l,4]thiazepine (III) with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV)
HN "OH
2HCI
IV in the presence of a base and sulfolane to give Quetiapine (V);
(iii) converting Quetiapine (V) to Quetiapine fumarate (I) by reacting it with fumaric acid in methanol
[Claim 3] 3. The process as claimed in claim 1 or 2, wherein the base is selected from potassium carbonate, sodium carbonate, lithium carbonate, sodium acetate, potassium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, potassium tert-butoxide,
1 ,8-diazobicyclo[5,4,0]undecene, N-benzyltrimethylammonium hydroxide, triethyl amine, tributyl amine, N,N-diisopropyl ethylamine, N,N-dimethylaniline, N,N-diethylaniline, pyridine, picolines, N,N-dimethylaminopyridine, N-methylmorpholine or mixtures thereof.
[Claim 4] 4. A process for purification of Quetiapine fumarate (I) comprising steps of
(a) heating impure Quetiapine fumarate (I) with methanol
(b) adding water dropwise till clear solution obtained
(c) cooling the reaction mixture to obtain pure Quetiapine fumarate (I)
[Claim 5] 5. A process for preparation of Quetiapine fumarate (I)
with l-(2-hydroxyethoxy)ethylpiperazine dihydrochloride (IV)
[Claim 6] 6. The process as claimed in claim 5, wherein the base is selected from potassium carbonate, sodium carbonate, lithium carbonate, sodium acetate, potassium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, sodium ethoxide, sodium iso- propoxide, potassium tert-butoxide, l,8-diazobicyclo[5,4,0]undecene, N-benzyltrimethylammonium hydroxide, triethyl amine, tributyl amine, N,N-diisopropyl ethylamine, N,N-dimethylaniline, N,N-diethylaniline, pyridine, picolines, N,N-dimethylaminopyridine, N-methylmorpholine or mixtures thereof .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1897/MUM/2008 | 2008-09-09 | ||
| IN1897MU2008 | 2008-09-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2010029458A2 true WO2010029458A2 (en) | 2010-03-18 |
| WO2010029458A3 WO2010029458A3 (en) | 2011-01-27 |
Family
ID=42005565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2009/053760 Ceased WO2010029458A2 (en) | 2008-09-09 | 2009-08-28 | A process for preparing quetiapine fumarate |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2010029458A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102432562A (en) * | 2011-11-28 | 2012-05-02 | 海南美兰史克制药有限公司 | Quetiapine fumarate compound and novel preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0516603D0 (en) * | 2005-08-12 | 2005-09-21 | Sandoz Ag | Processes for the preparation of organic compounds useful as serotonin receptor antagonists |
-
2009
- 2009-08-28 WO PCT/IB2009/053760 patent/WO2010029458A2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102432562A (en) * | 2011-11-28 | 2012-05-02 | 海南美兰史克制药有限公司 | Quetiapine fumarate compound and novel preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010029458A3 (en) | 2011-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009010988A1 (en) | An improved, industrially viable process for the preparation of high purity paliperidone | |
| US20060063927A1 (en) | Processes for preparing quetiapine and salts thereof | |
| JP6142459B2 (en) | Process for the preparation of 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide and its precursor | |
| JP5819284B2 (en) | Method for producing olopatadine | |
| WO2008001188A2 (en) | An improved process for the preparation of substantially pure aripiprazole | |
| US20140187568A1 (en) | Crystalline forms of bosentan salts and processes for their preparation | |
| WO2010029458A2 (en) | A process for preparing quetiapine fumarate | |
| CZ20013658A3 (en) | Synthesis and crystallization of compounds containing piperazine ring | |
| US20130184490A1 (en) | Process to prepare s-2-hydroxy-3-methoxy-3,3-diphenyl propionic acid | |
| US7045621B1 (en) | Process for producing dibenzothiazepine derivatives | |
| EP2245021B1 (en) | A process for the preparation of quetiapine | |
| WO2007020011A1 (en) | Processes for the preparation of thiazepines | |
| EP2370432A2 (en) | A process for preparing quetiapine fumarate | |
| PL195728B1 (en) | Method for manufacture of 11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine | |
| WO2008152434A1 (en) | Synthesis for the preparation of quetiapine | |
| EP1948628A1 (en) | Quetiapine hemifumarate purification by crystallization | |
| WO2003000670A1 (en) | A11-piperazinyldibenzo (b, f) (1, 4) oxazepines and thiazepines as atypical antipsychotic agents having low affinity for the d2 receptor | |
| JP4238978B2 (en) | Benzazepine compounds and process for producing the same | |
| US20120071649A1 (en) | Process for the preparation of quetiapine fumarate | |
| US20120259116A1 (en) | Novel Process for the Preparation of Paliperidone | |
| EP4281076A1 (en) | Processes for purification of bictegravir intermediates | |
| EP2749556B1 (en) | An improved process for the preparation of pure cyamemazine and salts thereof | |
| CN119285569A (en) | A type of five-membered nitrogen heterocyclic derivative and its preparation method and application | |
| WO2010085976A1 (en) | Process for the synthesis of quetiapine | |
| HU185725B (en) | Process for preparing 1,5-benzothiazepine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09812763 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09812763 Country of ref document: EP Kind code of ref document: A2 |